Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 54

1.

An RNA Aptamer-Based Biomarker Platform Demonstrates High Soluble CD25 Occupancy by IL2 in the Serum of Follicular Lymphoma Patients.

Veeramani S, Blackwell SE, Thiel WH, Yang ZZ, Ansell SM, Giangrande PH, Weiner GJ.

Cancer Immunol Res. 2019 Sep;7(9):1511-1522. doi: 10.1158/2326-6066.CIR-18-0821. Epub 2019 Aug 5.

PMID:
31383650
2.

mRNA Therapy Improves Metabolic and Behavioral Abnormalities in a Murine Model of Citrin Deficiency.

Cao J, An D, Galduroz M, Zhuo J, Liang S, Eybye M, Frassetto A, Kuroda E, Funahashi A, Santana J, Mihai C, Benenato KE, Kumarasinghe ES, Sabnis S, Salerno T, Coughlan K, Miracco EJ, Levy B, Besin G, Schultz J, Lukacs C, Guey L, Finn P, Furukawa T, Giangrande PH, Saheki T, Martini PGV.

Mol Ther. 2019 Jul 3;27(7):1242-1251. doi: 10.1016/j.ymthe.2019.04.017. Epub 2019 Apr 23.

PMID:
31056400
3.

Delivery of Cell-Specific Aptamers to the Arterial Wall with an Occlusion Perfusion Catheter.

Udofot O, Lin LH, Thiel WH, Erwin M, Turner E, Miller FJ Jr, Giangrande PH, Yazdani SK.

Mol Ther Nucleic Acids. 2019 Jun 7;16:360-366. doi: 10.1016/j.omtn.2019.03.005. Epub 2019 Mar 23.

4.

RNA inhibitors of nuclear proteins responsible for multiple organ dysfunction syndrome.

Urak KT, Blanco GN, Shubham S, Lin LH, Dassie JP, Thiel WH, Chen Y, Sonkar VK, Lei B, Murthy S, Gutierrez WR, Wilson ME, Stiber JA, Klesney-Tait J, Dayal S, Miller FJ Jr, Giangrande PH.

Nat Commun. 2019 Jan 10;10(1):116. doi: 10.1038/s41467-018-08030-y.

5.

Aptamers as Diagnostic Tools in Cancer.

Ruiz Ciancio D, Vargas MR, Thiel WH, Bruno MA, Giangrande PH, Mestre MB.

Pharmaceuticals (Basel). 2018 Sep 11;11(3). pii: E86. doi: 10.3390/ph11030086. Review.

6.

EphA2 receptor is a key player in the metastatic onset of Ewing sarcoma.

Garcia-Monclús S, López-Alemany R, Almacellas-Rabaiget O, Herrero-Martín D, Huertas-Martinez J, Lagares-Tena L, Alba-Pavón P, Hontecillas-Prieto L, Mora J, de Álava E, Rello-Varona S, Giangrande PH, Tirado OM.

Int J Cancer. 2018 Sep 1;143(5):1188-1201. doi: 10.1002/ijc.31405. Epub 2018 Apr 16.

7.

Rapid and Sensitive Detection of Breast Cancer Cells in Patient Blood with Nuclease-Activated Probe Technology.

Kruspe S, Dickey DD, Urak KT, Blanco GN, Miller MJ, Clark KC, Burghardt E, Gutierrez WR, Phadke SD, Kamboj S, Ginader T, Smith BJ, Grimm SK, Schappet J, Ozer H, Thomas A, McNamara JO 2nd, Chan CH, Giangrande PH.

Mol Ther Nucleic Acids. 2017 Sep 15;8:542-557. doi: 10.1016/j.omtn.2017.08.004. Epub 2017 Aug 12.

8.

Aptamer-siRNA Chimeras: Discovery, Progress, and Future Prospects.

Kruspe S, Giangrande PH.

Biomedicines. 2017 Aug 9;5(3). pii: E45. doi: 10.3390/biomedicines5030045. Review.

9.

Design and Preparation of Aptamer-siRNA Chimeras (AsiCs) for Targeted Cancer Therapy.

Kruspe S, Giangrande PH.

Methods Mol Biol. 2017;1632:175-186. doi: 10.1007/978-1-4939-7138-1_11.

PMID:
28730439
10.

Aptamers in Bordeaux, 24-25 June 2016.

Toulmé JJ, Giangrande PH, Mayer G, Suess B, Ducongé F, Sullenger B, de Franciscis V, Darfeuille F, Peyrin E.

Pharmaceuticals (Basel). 2017 Jan 20;10(1). pii: E14. doi: 10.3390/ph10010014.

11.

DNA methylation profiling identifies PTRF/Cavin-1 as a novel tumor suppressor in Ewing sarcoma when co-expressed with caveolin-1.

Huertas-Martínez J, Court F, Rello-Varona S, Herrero-Martín D, Almacellas-Rabaiget O, Sáinz-Jaspeado M, Garcia-Monclús S, Lagares-Tena L, Buj R, Hontecillas-Prieto L, Sastre A, Azorin D, Sanjuan X, López-Alemany R, Moran S, Roma J, Gallego S, Mora J, García Del Muro X, Giangrande PH, Peinado MA, Alonso J, de Alava E, Monk D, Esteller M, Tirado OM.

Cancer Lett. 2017 Feb 1;386:196-207. doi: 10.1016/j.canlet.2016.11.020. Epub 2016 Nov 25.

PMID:
27894957
12.

Aptamer-miRNA-212 Conjugate Sensitizes NSCLC Cells to TRAIL.

Iaboni M, Russo V, Fontanella R, Roscigno G, Fiore D, Donnarumma E, Esposito CL, Quintavalle C, Giangrande PH, de Franciscis V, Condorelli G.

Mol Ther Nucleic Acids. 2016 Mar 8;5:e289. doi: 10.1038/mtna.2016.5.

13.

Structural computational modeling of RNA aptamers.

Xu X, Dickey DD, Chen SJ, Giangrande PH.

Methods. 2016 Jul 1;103:175-9. doi: 10.1016/j.ymeth.2016.03.004. Epub 2016 Mar 10.

14.

In vitro RNA SELEX for the generation of chemically-optimized therapeutic RNA drugs.

Urak KT, Shore S, Rockey WM, Chen SJ, McCaffrey AP, Giangrande PH.

Methods. 2016 Jul 1;103:167-74. doi: 10.1016/j.ymeth.2016.03.003. Epub 2016 Mar 10.

15.

AFBI assay - Aptamer Fluorescence Binding and Internalization assay for cultured adherent cells.

Thiel WH, Giangrande PH.

Methods. 2016 Jul 1;103:180-7. doi: 10.1016/j.ymeth.2016.03.005. Epub 2016 Mar 10.

16.

Smooth Muscle Cell-targeted RNA Aptamer Inhibits Neointimal Formation.

Thiel WH, Esposito CL, Dickey DD, Dassie JP, Long ME, Adam J, Streeter J, Schickling B, Takapoo M, Flenker KS, Klesney-Tait J, Franciscis Vd, Miller FJ Jr, Giangrande PH.

Mol Ther. 2016 Apr;24(4):779-87. doi: 10.1038/mt.2015.235. Epub 2016 Jan 6.

17.

Oligonucleotide aptamers: A next-generation technology for the capture and detection of circulating tumor cells.

Dickey DD, Giangrande PH.

Methods. 2016 Mar 15;97:94-103. doi: 10.1016/j.ymeth.2015.11.020. Epub 2015 Nov 26. Review.

18.

Analyzing HT-SELEX data with the Galaxy Project tools--A web based bioinformatics platform for biomedical research.

Thiel WH, Giangrande PH.

Methods. 2016 Mar 15;97:3-10. doi: 10.1016/j.ymeth.2015.10.008. Epub 2015 Oct 23.

19.

Method for Confirming Cytoplasmic Delivery of RNA Aptamers.

Dickey DD, Thomas GS, Dassie JP, Giangrande PH.

Methods Mol Biol. 2016;1364:209-17. doi: 10.1007/978-1-4939-3112-5_17.

20.

Arresting the colonial destiny of metastatic seeds with DNA aptamers.

Condorelli G, Giangrande PH, de Franciscis V.

Mol Ther. 2015 Jun;23(6):982-984. doi: 10.1038/mt.2015.85. No abstract available.

21.

Cell-internalization SELEX: method for identifying cell-internalizing RNA aptamers for delivering siRNAs to target cells.

Thiel WH, Thiel KW, Flenker KS, Bair T, Dupuy AJ, McNamara JO 2nd, Miller FJ, Giangrande PH.

Methods Mol Biol. 2015;1218:187-99. doi: 10.1007/978-1-4939-1538-5_11.

22.

Targeted inhibition of prostate cancer metastases with an RNA aptamer to prostate-specific membrane antigen.

Dassie JP, Hernandez LI, Thomas GS, Long ME, Rockey WM, Howell CA, Chen Y, Hernandez FJ, Liu XY, Wilson ME, Allen LA, Vaena DA, Meyerholz DK, Giangrande PH.

Mol Ther. 2014 Nov;22(11):1910-22. doi: 10.1038/mt.2014.117. Epub 2014 Jun 23.

23.

Multifunctional aptamer-miRNA conjugates for targeted cancer therapy.

Esposito CL, Cerchia L, Catuogno S, De Vita G, Dassie JP, Santamaria G, Swiderski P, Condorelli G, Giangrande PH, de Franciscis V.

Mol Ther. 2014 Jun;22(6):1151-1163. doi: 10.1038/mt.2014.5. Epub 2014 Jan 20.

24.

Current progress on aptamer-targeted oligonucleotide therapeutics.

Dassie JP, Giangrande PH.

Ther Deliv. 2013 Dec;4(12):1527-46. doi: 10.4155/tde.13.118. Review.

25.

Identification of RNA aptamers that internalize into HPV-16 E6/E7 transformed tonsillar epithelial cells.

Gourronc FA, Rockey WM, Thiel WH, Giangrande PH, Klingelhutz AJ.

Virology. 2013 Nov;446(1-2):325-33. doi: 10.1016/j.virol.2013.08.015. Epub 2013 Sep 8.

26.

Methods for Evaluating Cell-Specific, Cell-Internalizing RNA Aptamers.

Hernandez LI, Flenker KS, Hernandez FJ, Klingelhutz AJ, McNamara JO 2nd, Giangrande PH.

Pharmaceuticals (Basel). 2013 Mar 14;6(3):295-319.

27.

Rapid identification of cell-specific, internalizing RNA aptamers with bioinformatics analyses of a cell-based aptamer selection.

Thiel WH, Bair T, Peek AS, Liu X, Dassie J, Stockdale KR, Behlke MA, Miller FJ Jr, Giangrande PH.

PLoS One. 2012;7(9):e43836. doi: 10.1371/journal.pone.0043836. Epub 2012 Sep 4.

28.

RNA aptamer-based functional ligands of the neurotrophin receptor, TrkB.

Huang YZ, Hernandez FJ, Gu B, Stockdale KR, Nanapaneni K, Scheetz TE, Behlke MA, Peek AS, Bair T, Giangrande PH, McNamara JO 2nd.

Mol Pharmacol. 2012 Oct;82(4):623-35. Epub 2012 Jun 29.

29.

Delivery of chemo-sensitizing siRNAs to HER2+-breast cancer cells using RNA aptamers.

Thiel KW, Hernandez LI, Dassie JP, Thiel WH, Liu X, Stockdale KR, Rothman AM, Hernandez FJ, McNamara JO 2nd, Giangrande PH.

Nucleic Acids Res. 2012 Jul;40(13):6319-37. doi: 10.1093/nar/gks294. Epub 2012 Mar 30.

30.

Rational truncation of an RNA aptamer to prostate-specific membrane antigen using computational structural modeling.

Rockey WM, Hernandez FJ, Huang SY, Cao S, Howell CA, Thomas GS, Liu XY, Lapteva N, Spencer DM, McNamara JO, Zou X, Chen SJ, Giangrande PH.

Nucleic Acid Ther. 2011 Oct;21(5):299-314. doi: 10.1089/nat.2011.0313.

31.

Nucleotide bias observed with a short SELEX RNA aptamer library.

Thiel WH, Bair T, Wyatt Thiel K, Dassie JP, Rockey WM, Howell CA, Liu XY, Dupuy AJ, Huang L, Owczarzy R, Behlke MA, McNamara JO, Giangrande PH.

Nucleic Acid Ther. 2011 Aug;21(4):253-63. doi: 10.1089/nat.2011.0288. Epub 2011 Jun 28.

32.

Synthesis and radiolabeling of chelator-RNA aptamer bioconjugates with copper-64 for targeted molecular imaging.

Rockey WM, Huang L, Kloepping KC, Baumhover NJ, Giangrande PH, Schultz MK.

Bioorg Med Chem. 2011 Jul 1;19(13):4080-90. doi: 10.1016/j.bmc.2011.05.010. Epub 2011 May 14.

33.

Intracellular delivery of RNA-based therapeutics using aptamers.

Thiel KW, Giangrande PH.

Ther Deliv. 2010 Dec;1(6):849-61. doi: 10.4155/tde.10.61. Review.

34.

Induction of tumour immunity by targeted inhibition of nonsense-mediated mRNA decay.

Pastor F, Kolonias D, Giangrande PH, Gilboa E.

Nature. 2010 May 13;465(7295):227-30. doi: 10.1038/nature08999.

35.

Systemic administration of optimized aptamer-siRNA chimeras promotes regression of PSMA-expressing tumors.

Dassie JP, Liu XY, Thomas GS, Whitaker RM, Thiel KW, Stockdale KR, Meyerholz DK, McCaffrey AP, McNamara JO 2nd, Giangrande PH.

Nat Biotechnol. 2009 Sep;27(9):839-49. doi: 10.1038/nbt.1560. Epub 2009 Aug 23.

36.

Therapeutic applications of DNA and RNA aptamers.

Thiel KW, Giangrande PH.

Oligonucleotides. 2009 Sep;19(3):209-22. doi: 10.1089/oli.2009.0199. Review.

37.

Cell-specific aptamers for targeted therapies.

Cerchia L, Giangrande PH, McNamara JO, de Franciscis V.

Methods Mol Biol. 2009;535:59-78. doi: 10.1007/978-1-59745-557-2_5. Review.

38.

A role for Myc in facilitating transcription activation by E2F1.

Leung JY, Ehmann GL, Giangrande PH, Nevins JR.

Oncogene. 2008 Jul 10;27(30):4172-9. doi: 10.1038/onc.2008.55. Epub 2008 Mar 17.

PMID:
18345030
39.

Multivalent 4-1BB binding aptamers costimulate CD8+ T cells and inhibit tumor growth in mice.

McNamara JO, Kolonias D, Pastor F, Mittler RS, Chen L, Giangrande PH, Sullenger B, Gilboa E.

J Clin Invest. 2008 Jan;118(1):376-86.

40.

RNA aptamer-targeted inhibition of NF-kappa B suppresses non-small cell lung cancer resistance to doxorubicin.

Mi J, Zhang X, Rabbani ZN, Liu Y, Reddy SK, Su Z, Salahuddin FK, Viles K, Giangrande PH, Dewhirst MW, Sullenger BA, Kontos CD, Clary BM.

Mol Ther. 2008 Jan;16(1):66-73. Epub 2007 Oct 2.

41.

Distinct roles of E2F proteins in vascular smooth muscle cell proliferation and intimal hyperplasia.

Giangrande PH, Zhang J, Tanner A, Eckhart AD, Rempel RE, Andrechek ER, Layzer JM, Keys JR, Hagen PO, Nevins JR, Koch WJ, Sullenger BA.

Proc Natl Acad Sci U S A. 2007 Aug 7;104(32):12988-93. Epub 2007 Jul 25.

42.

Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras.

McNamara JO 2nd, Andrechek ER, Wang Y, Viles KD, Rempel RE, Gilboa E, Sullenger BA, Giangrande PH.

Nat Biotechnol. 2006 Aug;24(8):1005-15. Epub 2006 Jun 25.

PMID:
16823371
43.

Targeted inhibition of alphavbeta3 integrin with an RNA aptamer impairs endothelial cell growth and survival.

Mi J, Zhang X, Giangrande PH, McNamara JO 2nd, Nimjee SM, Sarraf-Yazdi S, Sullenger BA, Clary BM.

Biochem Biophys Res Commun. 2005 Dec 16;338(2):956-63. Epub 2005 Oct 21.

PMID:
16256939
44.

Temporal control of cell cycle gene expression mediated by E2F transcription factors.

Zhu W, Giangrande PH, Nevins JR.

Cell Cycle. 2005 May;4(5):633-6. Epub 2005 May 2.

PMID:
15876877
45.

A role for E2F6 in distinguishing G1/S- and G2/M-specific transcription.

Giangrande PH, Zhu W, Schlisio S, Sun X, Mori S, Gaubatz S, Nevins JR.

Genes Dev. 2004 Dec 1;18(23):2941-51.

46.

E2Fs link the control of G1/S and G2/M transcription.

Zhu W, Giangrande PH, Nevins JR.

EMBO J. 2004 Nov 24;23(23):4615-26. Epub 2004 Oct 28.

47.

Combinatorial gene control involving E2F and E Box family members.

Giangrande PH, Zhu W, Rempel RE, Laakso N, Nevins JR.

EMBO J. 2004 Mar 24;23(6):1336-47. Epub 2004 Mar 4.

48.

Identification of E-box factor TFE3 as a functional partner for the E2F3 transcription factor.

Giangrande PH, Hallstrom TC, Tunyaplin C, Calame K, Nevins JR.

Mol Cell Biol. 2003 Jun;23(11):3707-20.

49.
50.

The A and B isoforms of the human progesterone receptor: two functionally different transcription factors encoded by a single gene.

Giangrande PH, McDonnell DP.

Recent Prog Horm Res. 1999;54:291-313; discussion 313-4. Review.

PMID:
10548881

Supplemental Content

Loading ...
Support Center